



Postage and fee required. This correspondence is being deposited with the US Postal Service with sufficient postage as first class mail in an envelope addressed to Box RCE, the Commissioner for Patents, Washington, D.C. 20231, on the date shown below.

Date: September 25, 2002

By: *Carol A. See*
Carol A. See

PATENT
Docket No. GC527C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
)	
Estell et al.)	Group Art Unit: 1644
)	
Serial No.: 09/500,135)	Examiner: Saunders, D.
)	
Filed: February 8, 2000)	
)	
For: Proteins Producing an Altered)	
Immunogenic Response and Methods)	
of Making and Using the Same)	

TERMINAL DISCLAIMER

Box RCE
Commissioner for Patents
Washington, D.C. 20231

The undersigned of Genencor International, Inc., Palo Alto, California (the successor to all rights of Genencor, Inc., a wholly owned subsidiary of Genencor International, Inc.), represents that Genencor International, Inc. is the assigned and exclusive owner of the entire right, title and interest of, in and to U.S. Patent Application Serial No. 09/500,135 indicated by the Assignments attached. Genencor International, Inc. hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of U.S. Patent Application No. 09/060,854 filed on April 15, 1998, also assigned to and owned by Genencor International, Inc., as indicated by the assignment records (Reel 9657, Frame 0874) and U.S. Patent Application No. 09/255,501, filed on February 23, 1999, also assigned to and owned by Genencor International, Inc., as indicated by the assignment records (Reel 9623, Frame 0578) of the U.S. Patent and Trademark Office, and hereby agrees that any patent so granted in the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to the

10/01/2002 CNGUYEN 00000134 071048 09500135

02 FC:148 110.00 CH
GC527C1 td

above-identified U.S. Patent, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

The undersigned has reviewed all the evidentiary documents referred to in the Terminal Disclaimer and it is certified to the best of the undersigned's knowledge and belief, title is in the Petitioner as described above.

The undersigned (whose title is supplied below) is empowered to act on behalf of the Petitioner.

Please charge the fee required by 37 CFR §1.20(d) to Deposit Account No. 07-1048. This document is submitted in triplicate. **-OR-** The fee required by 37 CFR §1.20(d) is authorized in the Transmittal Letter, submitted herewith in triplicate.

Date: 23 September 2002

By: Margaret A. Horn
Margaret A. Horn

Vice President

Title: Assistant General Counsel